Compare Capri Holdings Ltd (CPRI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Capri Holdings Ltd trades at $14.99 (market cap $1.64B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 78.1× Capri Holdings Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CPRI | VRTX | |
|---|---|---|
Market Cap | $1.64B | $128.16B |
Volume | 1,891,363 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $557.96 |
52-Week Low | $12.71 | $407.37 |
Typical Hold Time | 41 Days | 120 Days |
Enterprise Value | $2.92B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up slightly by 0.07% today, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue declined to $4.44 billion in 2025, and net income was negative $1.18 billion, though 2026 projections show a return to profitability. The company's balance sheet shows total assets of $5.21 billion against liabilities of $4.84 billion, with a high ROE of 252.89% but modest net income margin of 4.44%.
The outlook is mixed: analyst consensus is a Buy with a $20.57 price target, implying significant upside, but recent news highlights turnaround risks and a lowered 2027 sales view. Key risks include Michael Kors brand weakness and competitive pressures in the luxury sector. Cash flow trends show consistent negative net cash flow, adding to execution concerns amid efforts to revitalize brands.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
